Biogen beats quarterly profit estimates, Alzheimer's drug sales jump

The company also said its Alzheimer's drug Leqembi, developed with Japanese partner Eisai, recorded global sales of about $19 million, nearly tripling from the fourth quarter of 2023. The number of patients on the therapy have increased nearly 2.5 times since the end of 2023, Biogen said. Biogen and Eisai also intend to increase their sales force as they aim for 100,000 patients by 2026.